PE20150767A1 - Inhibidores de gdf-8 - Google Patents
Inhibidores de gdf-8Info
- Publication number
- PE20150767A1 PE20150767A1 PE2015000455A PE2015000455A PE20150767A1 PE 20150767 A1 PE20150767 A1 PE 20150767A1 PE 2015000455 A PE2015000455 A PE 2015000455A PE 2015000455 A PE2015000455 A PE 2015000455A PE 20150767 A1 PE20150767 A1 PE 20150767A1
- Authority
- PE
- Peru
- Prior art keywords
- indazole
- pyridin
- ethoxy
- inhibitors
- independently
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title abstract 2
- 108010056852 Myostatin Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- VPAOPHOXRAOUQD-UHFFFAOYSA-N 5-[5-ethoxy-2-(2-fluorophenyl)pyridin-3-yl]-1h-indazole Chemical compound C=1C=C2NN=CC2=CC=1C1=CC(OCC)=CN=C1C1=CC=CC=C1F VPAOPHOXRAOUQD-UHFFFAOYSA-N 0.000 abstract 1
- XOYJYKHQAVSOHJ-UHFFFAOYSA-N 5-[5-ethoxy-2-(4-fluoro-3-methylphenyl)pyridin-3-yl]-1h-indazole Chemical compound C=1C=C2NN=CC2=CC=1C1=CC(OCC)=CN=C1C1=CC=C(F)C(C)=C1 XOYJYKHQAVSOHJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Abstract
La invencion describe inhibidores de GCF-8 de la formula (I), y sus sales farmaceuticamente aceptables, en donde n es 1-4; R1y R2 son cada uno, de modo independiente, H, halogeno, nitro, entre otros; R5 y R6 son cada uno, de modo independiente, H, alquilo C1-C6, haloalquilo C1-C6, entre otros; X es N y Z es un anillo biciclico fusionado. Tambien se proporcionan composiciones farmaceuticas que los comprenden. Estos compuestos y composiciones son utiles en metodos para inhibir GDF-8 en una celula y metodos para tratar a un paciente que sufre de una enfermedad o trastorno, en donde el paciente se beneficiaria de un aumento de masa o fuerza de tejido muscular. Los compuestos preferidos son: 5-(5-Etoxi-2-(4-fluoro-3-metilfenil)piridin-3-il)-1H-indazol; 5-(5-Etoxi-2-(2-fluorofenil)piridin-3-il)-1H-indazol; entre otros
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261710449P | 2012-10-05 | 2012-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20150767A1 true PE20150767A1 (es) | 2015-05-15 |
Family
ID=49474701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015000455A PE20150767A1 (es) | 2012-10-05 | 2013-10-04 | Inhibidores de gdf-8 |
Country Status (20)
Country | Link |
---|---|
US (3) | US9145433B2 (es) |
EP (1) | EP2903978B1 (es) |
JP (2) | JP6457942B2 (es) |
KR (1) | KR20150072412A (es) |
CN (1) | CN104837832B (es) |
AU (1) | AU2013326867B2 (es) |
BR (1) | BR112015007182A2 (es) |
CA (1) | CA2887203A1 (es) |
CL (1) | CL2015000851A1 (es) |
EA (1) | EA201590693A1 (es) |
IL (1) | IL238031A0 (es) |
MA (1) | MA38050B1 (es) |
MX (1) | MX2015004151A (es) |
PE (1) | PE20150767A1 (es) |
PH (1) | PH12015500719A1 (es) |
SA (1) | SA515360229B1 (es) |
SG (1) | SG11201502527UA (es) |
TN (1) | TN2015000121A1 (es) |
WO (1) | WO2014055955A1 (es) |
ZA (1) | ZA201503041B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015004151A (es) * | 2012-10-05 | 2015-07-06 | Rigel Pharmaceuticals Inc | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). |
CR20160395A (es) | 2014-02-13 | 2016-12-20 | Incyte Corp | Ciclopropilaminas como inhibidores de lsd1 |
KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US10233170B2 (en) * | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
SG11201608658SA (en) | 2014-04-22 | 2016-11-29 | Univ Basel | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives |
CN103965192B (zh) * | 2014-05-20 | 2016-01-13 | 定陶县友帮化工有限公司 | 一种6-氯咪唑并[1,2-a]吡啶-3-甲酸的合成方法 |
CN103965191A (zh) * | 2014-05-20 | 2014-08-06 | 定陶县友帮化工有限公司 | 一种6-溴咪唑并[1,2-a]吡啶-3-甲酸的合成方法 |
CN103965190A (zh) * | 2014-05-20 | 2014-08-06 | 定陶县友帮化工有限公司 | 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法 |
CA2953177C (en) | 2014-06-23 | 2019-07-23 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
CN104402881B (zh) * | 2014-11-05 | 2016-04-20 | 定陶县友帮化工有限公司 | 一种3-醛基-6-溴咪唑并[1,2-a]吡啶-8-甲酸乙酯的合成方法 |
EP3259264B1 (en) * | 2015-02-20 | 2022-07-27 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
US9884868B2 (en) | 2015-03-02 | 2018-02-06 | Rigel Pharmaceuticals, Inc. | TGF-beta inhibitors |
MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
CN110402244B (zh) | 2015-08-12 | 2023-02-03 | 因赛特公司 | Lsd1抑制剂的盐 |
WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
WO2017091661A1 (en) * | 2015-11-25 | 2017-06-01 | Strovel Jeffrey William | Bicyclic bet bromodomain inhibitors and uses thereof |
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
US20190292179A1 (en) | 2016-07-21 | 2019-09-26 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
EP3492461A4 (en) * | 2016-07-29 | 2020-02-12 | Shanghai Yingli Pharmaceutical Co. Ltd. | NITROGEN HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
US11491025B2 (en) | 2016-10-25 | 2022-11-08 | Elevation Spine, Inc. | Intervertebral implant and method of use |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
PL3570834T3 (pl) | 2017-01-11 | 2022-05-23 | Alkermes, Inc. | Bicykliczne inhibitory deacetylazy histonowej |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10631999B2 (en) | 2017-06-30 | 2020-04-28 | Elevation Spine, Inc. | Systems and methods for inserting an interbody spacer and bone plate assembly |
RS63343B1 (sr) | 2017-08-07 | 2022-07-29 | Alkermes Inc | Biciklični inhibitori histonske deacetilaze |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
PL3755703T3 (pl) | 2018-02-20 | 2022-11-07 | Incyte Corporation | Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
AU2020326703A1 (en) | 2019-08-06 | 2022-02-17 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
CN112225736B (zh) * | 2020-11-12 | 2022-04-15 | 山东省科学院菏泽分院 | 一种6-溴咪唑并[1.2-a]吡啶-3-甲醛的制备方法 |
WO2023131868A1 (en) * | 2022-01-07 | 2023-07-13 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of glut9 for treatment of disease |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW458977B (en) * | 1997-04-16 | 2001-10-11 | Abbott Lab | 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds |
JP2002534385A (ja) * | 1999-01-08 | 2002-10-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
CA2359242C (en) | 1999-01-21 | 2009-12-08 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
JP2001081087A (ja) * | 1999-09-13 | 2001-03-27 | Sankio Chemical Co Ltd | 新規な2−(2−ピリジル)ピリミジン誘導体 |
WO2001057040A1 (en) * | 2000-02-03 | 2001-08-09 | Abbott Laboratories | 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
WO2002014282A1 (fr) * | 2000-08-11 | 2002-02-21 | Eisai Co., Ltd. | Composes 2-aminopyridine et leur utilisation comme medicaments |
AU9502601A (en) * | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
JP4317752B2 (ja) * | 2001-10-15 | 2009-08-19 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 無脊椎害虫を防除するためのイミノベンゾオキサジン、イミノベンズチアジンおよびイミノキナゾリン |
EP1492784A4 (en) * | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
WO2005016862A1 (en) * | 2003-08-14 | 2005-02-24 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivative and use thereof |
US7799772B2 (en) | 2003-12-18 | 2010-09-21 | Janssen Pharmaceutica N.V. | Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents |
WO2005085227A1 (en) * | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
WO2007076086A2 (en) * | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Tricyclic spiro compounds useful as transforming growth factor modulators |
EP2044056B1 (en) * | 2006-07-14 | 2012-08-22 | Novartis AG | Pyrimidine derivatives as alk-5 inhibitors |
FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
AU2007315234A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
EP2121669A2 (en) * | 2007-01-30 | 2009-11-25 | Biogen Idec MA, Inc. | Furanone compounds and methods of making and using the same |
KR101511074B1 (ko) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Mcl-1 억제제 |
JP5090528B2 (ja) | 2007-07-26 | 2012-12-05 | ノバルティス アーゲー | ALK4またはALK5が介在する疾患を処置するための2、3、7位置換イミダゾ[1,2−b]ピリダジン類 |
US8263595B2 (en) | 2007-08-31 | 2012-09-11 | Merck Serono Sa | Triazolopyridine compounds and their use as ask inhibitors |
WO2009032653A1 (en) * | 2007-08-31 | 2009-03-12 | Smith Kline Beecham Corporation | Inhibitors of akt activity |
WO2009051705A1 (en) * | 2007-10-18 | 2009-04-23 | Merck & Co., Inc. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
KR101015858B1 (ko) * | 2008-06-26 | 2011-02-23 | 제일모직주식회사 | 유기 화합물, 및 이를 포함하는 유기 광전 소자 |
US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
JP5731399B2 (ja) * | 2008-12-30 | 2015-06-10 | チェイル インダストリーズ インコーポレイテッド | 新規な有機光電素子用化合物およびこれを含む有機光電素子 |
WO2010094695A1 (en) | 2009-02-17 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases |
EP2516441B1 (en) * | 2009-12-23 | 2015-01-21 | Elan Pharmaceuticals Inc. | Pteridinones as inhibitors of polo-like kinase |
WO2011096196A1 (en) * | 2010-02-02 | 2011-08-11 | Oncotherapy Science, Inc. | Lsd1 for target genes of cancer therapy and diagnosis |
ES2667049T3 (es) * | 2010-02-05 | 2018-05-09 | Merck Patent Gmbh | Derivados de heteroaril-[1,8]naftiridina |
US8575203B2 (en) | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
EA201300080A1 (ru) * | 2010-07-05 | 2013-06-28 | Мерк Патент Гмбх | Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами |
MX2015004151A (es) * | 2012-10-05 | 2015-07-06 | Rigel Pharmaceuticals Inc | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). |
-
2013
- 2013-10-04 MX MX2015004151A patent/MX2015004151A/es unknown
- 2013-10-04 BR BR112015007182A patent/BR112015007182A2/pt not_active IP Right Cessation
- 2013-10-04 PE PE2015000455A patent/PE20150767A1/es not_active Application Discontinuation
- 2013-10-04 SG SG11201502527UA patent/SG11201502527UA/en unknown
- 2013-10-04 KR KR1020157011251A patent/KR20150072412A/ko not_active Application Discontinuation
- 2013-10-04 JP JP2015535846A patent/JP6457942B2/ja active Active
- 2013-10-04 WO PCT/US2013/063585 patent/WO2014055955A1/en active Application Filing
- 2013-10-04 AU AU2013326867A patent/AU2013326867B2/en not_active Ceased
- 2013-10-04 US US14/046,834 patent/US9145433B2/en active Active
- 2013-10-04 CN CN201380063519.8A patent/CN104837832B/zh active Active
- 2013-10-04 EA EA201590693A patent/EA201590693A1/ru unknown
- 2013-10-04 CA CA2887203A patent/CA2887203A1/en active Pending
- 2013-10-04 EP EP13780264.1A patent/EP2903978B1/en active Active
-
2015
- 2015-03-27 TN TNP2015000121A patent/TN2015000121A1/fr unknown
- 2015-03-30 IL IL238031A patent/IL238031A0/en unknown
- 2015-03-31 PH PH12015500719A patent/PH12015500719A1/en unknown
- 2015-04-02 SA SA515360229A patent/SA515360229B1/ar unknown
- 2015-04-02 CL CL2015000851A patent/CL2015000851A1/es unknown
- 2015-04-29 MA MA38050A patent/MA38050B1/fr unknown
- 2015-05-04 ZA ZA2015/03041A patent/ZA201503041B/en unknown
- 2015-08-24 US US14/833,689 patent/US9518040B2/en active Active
-
2017
- 2017-07-13 US US15/366,981 patent/US9878992B2/en active Active
-
2018
- 2018-11-02 JP JP2018207133A patent/JP2019048841A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US9878992B2 (en) | 2018-01-30 |
CA2887203A1 (en) | 2014-04-10 |
AU2013326867A1 (en) | 2015-05-21 |
US20140107073A1 (en) | 2014-04-17 |
EP2903978A1 (en) | 2015-08-12 |
ZA201503041B (en) | 2017-11-29 |
EA201590693A1 (ru) | 2015-08-31 |
CN104837832B (zh) | 2019-04-26 |
US9145433B2 (en) | 2015-09-29 |
IL238031A0 (en) | 2015-05-31 |
KR20150072412A (ko) | 2015-06-29 |
US9518040B2 (en) | 2016-12-13 |
US20160052909A1 (en) | 2016-02-25 |
SG11201502527UA (en) | 2015-04-29 |
CN104837832A (zh) | 2015-08-12 |
WO2014055955A1 (en) | 2014-04-10 |
BR112015007182A2 (pt) | 2017-07-04 |
EP2903978B1 (en) | 2022-12-07 |
JP2019048841A (ja) | 2019-03-28 |
CL2015000851A1 (es) | 2015-08-28 |
PH12015500719A1 (en) | 2015-05-18 |
JP6457942B2 (ja) | 2019-01-23 |
US20170342048A1 (en) | 2017-11-30 |
MX2015004151A (es) | 2015-07-06 |
JP2016500671A (ja) | 2016-01-14 |
MA38050B1 (fr) | 2017-01-31 |
AU2013326867B2 (en) | 2018-03-08 |
SA515360229B1 (ar) | 2015-11-25 |
MA38050A1 (fr) | 2016-06-30 |
TN2015000121A1 (en) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20150767A1 (es) | Inhibidores de gdf-8 | |
PE20161246A1 (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
CL2011002955A1 (es) | Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades. | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
UY32640A (es) | Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
EA201400182A1 (ru) | Производные пиридин-2(1н)-она в качестве ингибиторов jak | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
PE20191032A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos | |
CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
EA201692300A1 (ru) | Производные карбоксамида | |
CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
UY31824A (es) | Nuevos compuestos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |